Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen, Patrick J.; Daly, Robin M.; Dalla Via, Jack; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Fraser, Steve F. (2019). Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?. Calcified Tissue International, 105 (4), 403-411. DOI: 10.1007/s00223-019-00586-1
Published inCalcified Tissue International
© The Authors, 2019
Androgen deprivation therapy (ADT) for prostate cancer (PCa) can compromise muscle health. Hence, we aimed to quantify the prevalence of sarcopenia (i.e., compromised lean mass, muscle strength, and physical function) in ADT-treated (> 12 week) men (n = 70) compared to similarly aged non-ADT-treated PCa (n = 52) and healthy controls (n = 70). Lean and fat mass were quantified by dual-energy X-ray absorptiometry. Muscle strength and function were measured using handgrip dynamometry and gait speed, respectively. Sarcopenia was defined as low adjusted appendicular lean mass [ALM; height-adjusted (ALMI), body mass index-adjusted (ALMBMI) and height and fat mass-adjusted (ALMHFM)] with weak handgrip strength and/or slow gait speed according to the following criteria: European Working Group on Sarcopenia in Older People [EWGSOP; both 2010 (EWGSOP1) and 2018 (EWGSOP2)], Foundation for the National Institutes of Health (FNIH) and International Working Group on Sarcopenia (IWGS). Overall the prevalence of sarcopenia was low and did not differ between the three groups. Only two (3.2%) ADT-treated men presented with sarcopenia as per EWGSOP1 and FNIH criteria, whereas no cases were observed using EWGSOP2 and IWGS criteria. The prevalence of low ALMBMI was greater in ADT-treated men (32%) compared to PCa (15%; P = 0.037) and healthy controls (7.1%; P < 0.001). Similarly, low ALMHFM was greater in ADT-treated men (29%) compared to healthy controls only (13%; P = 0.019). There was also a low prevalence of weak muscle strength and slow gait speed (0.0–11%) in all men, with no differences between the groups. Based on these findings, an adiposity-based adjustment of ALM is recommended to quantify risk of adverse outcomes associated with ADT in these men. ...
PublisherSpringer New York LLC
Publication in research information system
MetadataShow full item record
- Liikuntatieteiden tiedekunta 
Additional information about fundingThis research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Showing items with similar title or keywords.
Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation : A 12-month RCT Via, Jack Dalla; Owen, Patrick J.; Daly, Robin M.; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Foulkes, Stephen J.; Millar, Jeremy L.; Murphy, Declan G.; Fraser, Steve F. (Lippincott Williams & Wilkins, 2021)Purpose Androgen deprivation therapy (ADT) for prostate cancer (PCa) has multiple adverse effects on musculoskeletal health. This 12-month randomised controlled trial aimed to assess the effects of multi-component exercise ...
The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer Owen, Patrick J.; Daly, Robin M.; Via, Jack Dalla; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Fraser, Steve F. (Wiley - VCH Verlag GmbH & Co. KGaA, 2019)Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may prospectively decrease absolute lean mass (LM) and increase absolute fat mass (FM). Given that estimates of LM by dual‐energy X‐ray absorptiometry ...
Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer patients : A secondary analysis of two randomized controlled trials Newton, Robert U.; Mavropalias, Georgios; Fragala, Maren S.; Kraemer, William J.; Häkkinen, Keijo; Taaffe, Dennis R.; Spry, Nigel; Joseph, David; Galvão, Daniel A. (Elsevier, 2021)Background Androgen deprivation therapy (ADT) contributes to lean mass loss and adiposity increases in prostate cancer patients. Radiotherapy during ADT might act synergistically and further worsen body composition. ...
Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy Via, Jack Dalla; Daly, Robin M.; Owen, Patrick J.; Mundell, Niamh L.; Rantalainen, Timo; Fraser, Steve F. (Elsevier Inc., 2019)Androgen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has ...
Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy : A Systematic Review and Meta-Analysis Chen, Ziyuan; Zhang, Yuan; Lu, Chunyan; Zeng, Hao; Schumann, Moritz; Cheng, Sulin (Frontiers Media, 2019)Introduction: Androgen deprivation therapy (ADT) is considered the basic treatment for advanced prostate cancer, but it is highly associated with detrimental changes in muscle mass and muscle strength. The aim of this ...